Revolution Medicines (RVMD) shares declined 9% in recent Monday trading after the company presented preliminary data for its RMC-6236 and RMC-6291 drug candidates in patients with several forms of cancer, including pancreatic ductal adenocarcinoma, colorectal, non-small cell lung cancer, and colorectal cancer.
The company reported updated clinical data for RMC-6236 from its Phase 1 study, which evaluated 76 patients with RAS-mutant pancreatic ductal adenocarcinoma treated with 300 mg daily.
Rash and gastrointestinal toxicities were the most common treatment-related adverse events observed, according to the company.
Additionally, data from 124 patients with RAS-mutant non-small cell lung cancer suggested that RMC-6236 was well tolerated at doses between 120 mg and 220 mg daily, but treatment-related adverse events increased at the 300 mg daily dose level.
The company said the phase 1 and phase 1b trials evaluated both RMC-6236 and RMC-6291 as monotherapies and in combination with Merck's (MRK) Keytruda chemotherapy, spanning multiple dosing levels.
The testing also spanned multiple dosing levels, generally finding there were no severe treatment-related adverse events and that the data support additional studies, it added.
Price: 52.66, Change: -5.19, Percent Change: -8.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.